Your session is about to expire
← Back to Search
Other
Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects
Phase 1
Waitlist Available
Research Sponsored by MBX Biosciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through day 40 (part a) or day 60 (part b)
Summary
This trial tests a new drug called MBX 2109, given as an injection under the skin, in healthy volunteers. The study aims to see how the drug is processed by the body, its effects, and if it is safe.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline through day 40 (part a) or day 60 (part b)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through day 40 (part a) or day 60 (part b)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Measures
Secondary study objectives
Measures 1
Measures 2
Trial Design
3Treatment groups
Experimental Treatment
Placebo Group
Group I: MBX 2109 (Part B)Experimental Treatment1 Intervention
Repeated ascending SC doses
Group II: MBX 2109 (Part A)Experimental Treatment1 Intervention
Single ascending SC doses
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MBX 2109 (Part A)
2021
Completed Phase 1
~80
MBX 2109 (Part B)
2021
Completed Phase 1
~80
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
MBX BiosciencesLead Sponsor
4 Previous Clinical Trials
212 Total Patients Enrolled
Mary Jane Geiger, MD, PhDStudy DirectorMBX Biosciences